These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1752746)

  • 1. Evidence of a neutron RBE of 70 (+/- 50) for solid-tumor induction at Hiroshima and Nagasaki and its implications for assessing the effective neutron quality factor.
    Zaider M
    Health Phys; 1991 Nov; 61(5):631-6. PubMed ID: 1752746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of possible modifications to the DS86 dosimetry on neutron risk and relative biological effectiveness.
    Hunter N; Charles MW
    J Radiol Prot; 2002 Dec; 22(4):357-70. PubMed ID: 12546224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutron relative biological effectiveness in Hiroshima and Nagasaki atomic bomb survivors: a critical review.
    Sasaki MS; Endo S; Hoshi M; Nomura T
    J Radiat Res; 2016 Nov; 57(6):583-595. PubMed ID: 27614201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutron versus gamma-ray risk estimates. Inferences from the cancer incidence and mortality data in Hiroshima.
    Kellerer AM; Nekolla E
    Radiat Environ Biophys; 1997 Jun; 36(2):73-83. PubMed ID: 9271794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of model and uncertainties of the gamma-ray and neutron dosimetry in relation to the chromosome aberrations data in Hiroshima and Nagasaki.
    Rühm W; Walsh L; Chomentowski M
    Radiat Environ Biophys; 2003 Jul; 42(2):119-28. PubMed ID: 12844221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Relative Biological Effectiveness of Neutrons across Organs of Varying Depth among the Atomic Bomb Survivors.
    Cordova KA; Cullings HM
    Radiat Res; 2019 Aug; 192(4):380-387. PubMed ID: 31390313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 1. Comparison of risk coefficients for site-specific cancer mortality based on the DS86 and T65DR shielded kerma and organ doses.
    Shimizu Y; Kato H; Schull WJ; Preston DL; Fujita S; Pierce DA
    Radiat Res; 1989 Jun; 118(3):502-24. PubMed ID: 2727272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective dose of A-bomb radiation in Hiroshima and Nagasaki as assessed by chromosomal effectiveness of spectrum energy photons and neutrons.
    Sasaki MS; Endo S; Ejima Y; Saito I; Okamura K; Oka Y; Hoshi M
    Radiat Environ Biophys; 2006 Jul; 45(2):79-91. PubMed ID: 16807767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors.
    Kellerer AM; Rühm W; Walsh L
    Health Phys; 2006 Jun; 90(6):554-64. PubMed ID: 16691103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of new Hiroshima and Nagasaki dose estimates: cancer risks and neutron RBE.
    Straume T; Dobson RL
    Health Phys; 1981 Oct; 41(4):666-71. PubMed ID: 7309524
    [No Abstract]   [Full Text] [Related]  

  • 11. Stable chromosome aberrations among A-bomb survivors: an update.
    Stram DO; Sposto R; Preston D; Abrahamson S; Honda T; Awa AA
    Radiat Res; 1993 Oct; 136(1):29-36. PubMed ID: 8210335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the impact of neutron relative biological effectiveness on all solid cancer mortality risks in the Japanese atomic bomb survivors.
    Hafner L; Walsh L; Rühm W
    Int J Radiat Biol; 2024; 100(1):61-71. PubMed ID: 37772764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrons at Hiroshima: how their disappearance affected risk estimates.
    Ellett WH
    Radiat Res; 1991 Oct; 128(1 Suppl):S147-52. PubMed ID: 1924742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late radiation responses in man: current evaluation from results from Hiroshima and Nagasaki.
    Schull WJ
    Adv Space Res; 1983; 3(8):231-9. PubMed ID: 11542750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accounting for neutron exposure in the Japanese atomic bomb survivors.
    Cullings HM; Pierce DA; Kellerer AM
    Radiat Res; 2014 Dec; 182(6):587-98. PubMed ID: 25409123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of changes in dosimetry on cancer mortality risk estimates in the atomic bomb survivors.
    Preston DL; Pierce DA
    Radiat Res; 1988 Jun; 114(3):437-66. PubMed ID: 3375435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutron-induced 63Ni in copper samples from Hiroshima and Nagasaki: a comprehensive presentation of results obtained at the Munich Maier-Leibnitz Laboratory.
    Rühm W; Carroll KL; Egbert SD; Faestermann T; Knie K; Korschinek G; Martinelli RE; Marchetti AA; McAninch JE; Rugel G; Straume T; Wallner A; Wallner C; Fujita S; Hasai H; Hoshi M; Shizuma K
    Radiat Environ Biophys; 2007 Nov; 46(4):327-38. PubMed ID: 17828415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates.
    Preston DL; Pierce DA; Shimizu Y; Cullings HM; Fujita S; Funamoto S; Kodama K
    Radiat Res; 2004 Oct; 162(4):377-89. PubMed ID: 15447045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation of low-dose extrapolation factors from analysis of curvature in the cancer incidence dose response in Japanese atomic bomb survivors.
    Little MP; Muirhead CR
    Int J Radiat Biol; 2000 Jul; 76(7):939-53. PubMed ID: 10923618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of neutrons in Hiroshima. Implications for the risk estimates.
    Kellerer AM
    C R Acad Sci III; 1999; 322(2-3):229-37. PubMed ID: 10196677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.